Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $15.92

Posted by Defense World Staff on Apr 23rd, 2023

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $15.92, but opened at $15.59. Janux Therapeutics shares last traded at $15.70, with a volume of 5,076 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages have recently commented on JANX. Wedbush began coverage on shares of Janux Therapeutics in a research note on Wednesday, April 5th. They set an “outperform” rating and a $24.00 price objective for the company. Bank of America lowered their price objective on shares of Janux Therapeutics from $29.00 to $26.00 in a research note on Friday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 13th.

Janux Therapeutics Price Performance

The company has a market capitalization of $644.60 million, a P/E ratio of -10.14 and a beta of 1.49. The stock’s 50 day moving average is $14.52 and its 200-day moving average is $15.50.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently bought and sold shares of JANX. JPMorgan Chase & Co. raised its stake in Janux Therapeutics by 34.9% in the first quarter. JPMorgan Chase & Co. now owns 17,926 shares of the company’s stock worth $256,000 after buying an additional 4,638 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Janux Therapeutics by 25.9% in the first quarter. Bank of New York Mellon Corp now owns 46,001 shares of the company’s stock worth $660,000 after purchasing an additional 9,464 shares during the period. MetLife Investment Management LLC grew its holdings in Janux Therapeutics by 100.2% in the first quarter. MetLife Investment Management LLC now owns 10,614 shares of the company’s stock worth $152,000 after purchasing an additional 5,312 shares during the period. Rhumbline Advisers grew its holdings in Janux Therapeutics by 46.9% in the first quarter. Rhumbline Advisers now owns 16,216 shares of the company’s stock worth $233,000 after purchasing an additional 5,179 shares during the period. Finally, BlackRock Inc. grew its holdings in Janux Therapeutics by 15.2% in the first quarter. BlackRock Inc. now owns 1,161,721 shares of the company’s stock worth $16,659,000 after purchasing an additional 153,460 shares during the period. 70.95% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

(Get Rating)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.